Jado Technologies (Germany) early-stage developer of small molecule allergy and antiinfective therapeutics, closed a $4.9M Series B financing. Participants include Peppermint Financial Partners, NRW Bank, Dresden Fonds, EMBL Ventures, ERP-Startfonds, Max Planck Society and MASA Life Science Ventures.